ECCS-50: Completed Phase II enrollment

Bimini’s Kerastem Technologies LLC company completed enrollment of 70 patients in the double-blind, sham-controlled, U.S. Phase II STYLE trial evaluating 500,000 and 1 million/cm 2 subcutaneous ADRCs....